2022
Using machine learning to predict heavy drinking during outpatient alcohol treatment
Roberts W, Zhao Y, Verplaetse T, Moore KE, Peltier MR, Burke C, Zakiniaeiz Y, McKee S. Using machine learning to predict heavy drinking during outpatient alcohol treatment. Alcohol Clinical And Experimental Research 2022, 46: 657-666. PMID: 35420710, PMCID: PMC9180421, DOI: 10.1111/acer.14802.Peer-Reviewed Original ResearchConceptsAlcohol use disorderHeavy drinkingTreatment outcomesInvasive assessment methodsOutpatient AUD treatmentLast monthOutpatient alcohol treatmentMultisite clinical trialAccurate clinical predictionsHeavy alcohol useSex differencesBi-weekly sessionsAlcohol treatment outcomesPatient characteristicsClinical outcomesClinical trialsClinical dataStratified analysisEffective treatmentPsychiatric disordersUse disordersAUD treatmentSubstantial sex differencesAlcohol treatmentFirst month
2020
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Alcohol Clinical And Experimental Research 2020, 45: 15-24. PMID: 33190310, PMCID: PMC7855436, DOI: 10.1111/acer.14514.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesTreatment seekersNontreatment seekersExpensive clinical trialsPatient populationAlcohol administrationClinical trialsMedication effectsClinical conditionsMedication developmentMedicationsHeavy drinkersMedication experimentsLaboratory screeningClinical realityAdministration guidelinesScreening researchDevelopment pipelineLaboratory studiesRiskGuidelinesParticipantsPharmacotherapyPopulationEthical guidelinesAssociations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study
Verplaetse TL, Peltier MR, Roberts W, Moore KE, Pittman BP, McKee SA. Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Nicotine & Tobacco Research 2020, 22: 1316-1321. PMID: 32152625, PMCID: PMC7364844, DOI: 10.1093/ntr/ntaa022.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioFaster nicotine metabolismHigher nicotine metabolite ratioE-cigarette useCigarette smoking statusSlower nicotine metabolismNicotine metabolismE-cigarettesSmoking statusCigarette smokingMetabolite ratiosE-cigarette use statusPopulation-based studyLongitudinal cohort studyWave 1Cigarette smoking behaviorCohort studyClinical trialsTobacco usePATH studyHealth StudySmoking behaviorEarly interventionUS populationCombustible cigarettes
2019
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesMobile alcohol biosensors and pharmacotherapy development research
Roberts W, McKee SA. Mobile alcohol biosensors and pharmacotherapy development research. Alcohol 2018, 81: 149-160. PMID: 31679765, PMCID: PMC6842067, DOI: 10.1016/j.alcohol.2018.07.012.Peer-Reviewed Original Research
2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDA
2014
Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review
Weinberger AH, Smith PH, Kaufman M, McKee SA. Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review. Experimental And Clinical Psychopharmacology 2014, 22: 373-383. PMID: 25133506, PMCID: PMC4180800, DOI: 10.1037/a0037692.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchNicotine patchCessation outcomesClinical trialsSmoking cessationSmoking cessation treatmentMenstrual cycle phaseCessation treatmentSex-related variablesInclusion criteriaMEDLINE searchSmoking treatmentSide effectsBetter outcomesTreatment efficacyConsideration of sexSystematic reviewPotential articlesInclusion of sexSkin irritationMore womenTrialsOutcomesSexWomenA behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers
Weinberger AH, Pittman B, Mazure CM, McKee SA. A behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers. Addiction Research & Theory 2014, 23: 108-114. PMID: 25904837, PMCID: PMC4402999, DOI: 10.3109/16066359.2014.933813.Peer-Reviewed Original ResearchFemale smokersPoint prevalence smoking abstinenceStage II clinical trialsEnd of treatmentDaily cigarette smokersTreatment development studyNovel behavioral treatmentPrimary outcomeCigarette smokersSmoking abstinenceSmoking interventionsClinical trialsMayo ClinicStandard counselingRisk counselingSmoking treatmentSmoking outcomesSmokersBehavioral treatmentManualized treatmentTreatment developmentAcceptability studyCounseling conditionMonthsGreater reduction
2012
Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010
Weinberger AH, Mazure CM, Morlett A, McKee SA. Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010. Nicotine & Tobacco Research 2012, 15: 1014-1031. PMID: 23100459, PMCID: PMC3693502, DOI: 10.1093/ntr/nts213.Peer-Reviewed Original ResearchConceptsRelationship of depressionSmoking cessation outcomesCessation outcomesSmoking cessationTreatment outcomesCurrent major depressive disorderMajor depressive disorderCurrent depression symptomsClinical trialsDepressive disorderMinor depressionMajor depressionInclusion criteriaMEDLINE searchPast diagnosisTreatment approachesDepression symptomsHealth-related risksMajority of studiesPotential articlesDepressionRacial differencesOutcomesCessationSmokers
2010
Differences in smoking expectancies in smokers with and without a history of major depression
Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. Addictive Behaviors 2010, 36: 434-437. PMID: 21239119, PMCID: PMC3052745, DOI: 10.1016/j.addbeh.2010.12.024.Peer-Reviewed Original ResearchConceptsHistory of depressionMajor depressive disorderSmoking cessationClinical trialsSmoking expectanciesAdult cigarette smokersInteraction of depressionSmoking cessation behaviorsLower quit ratesMDD- smokersCigarette smokersDepressive disorderAdult smokersCognitive-behavioral treatmentMajor depressionQuit ratesCessation behaviorsSmokersSelegiline hydrochlorideSmokingSecondary aimEvidence high ratesDepressionSmoking beliefsHigh rateExamining antidepressant drug response by smoking status: why is it important and how often is it done?
Weinberger AH, McKee SA, Picciotto MR, Mazure CM. Examining antidepressant drug response by smoking status: why is it important and how often is it done? Journal Of Psychopharmacology 2010, 25: 1269-1276. PMID: 21169392, PMCID: PMC3256572, DOI: 10.1177/0269881110389347.Peer-Reviewed Original ResearchConceptsSmoking statusImpact of smokingEffect of smokingNeurobiology of depressionAntidepressant treatment outcomeAntidepressant drug responsePharmacological intervention studiesPharmacological trialsClinical trialsTreatment outcomesMEDLINE searchNicotine dependenceSmokingTargeted treatmentIntervention studiesTreatment studiesDrug responseDepressionOutcomesTreatment researchTrialsStatusTreatmentAntidepressantsPharmacotherapyInclusion of Women and Gender-Specific Analyses in Randomized Clinical Trials of Treatments for Depression
Weinberger AH, McKee SA, Mazure CM. Inclusion of Women and Gender-Specific Analyses in Randomized Clinical Trials of Treatments for Depression. Journal Of Women's Health 2010, 19: 1727-1732. PMID: 20799923, PMCID: PMC2936499, DOI: 10.1089/jwh.2009.1784.Peer-Reviewed Original ResearchConceptsRecent randomized clinical trialsRandomized clinical trialsClinical trialsGender-specific analysisDepression treatmentHealth (NIH) Revitalization ActCost of depressionInterventional studyInclusion of womenHigh prevalenceTreatment responseMEDLINE searchTreatment efficacyGender differencesPossible gender differencesDepression researchTrialsWomenDepressionNational InstituteRevitalization ActTreatmentFemale participantsOutcomesGender
2008
Risk factors for treatment failure in smokers: Relationship to alcohol use and to lifetime history of an alcohol use disorder
Leeman RF, McKee SA, Toll BA, Krishnan-Sarin S, Cooney JL, Makuch RW, O'Malley SS. Risk factors for treatment failure in smokers: Relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine & Tobacco Research 2008, 10: 1793-1809. PMID: 19023831, PMCID: PMC2764010, DOI: 10.1080/14622200802443742.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderAUD historyCessation relapseUse disordersDrinking daysModerate drinkingAlcohol useSustained-release bupropionLifetime alcohol use disorderModerate alcohol usersRandomized clinical trialsAlcohol use categoriesProbability of smokingSmoking cessation failureTreatment failureAlcohol use levelsRisk factorsClinical trialsHazardous patternsTreatment periodHazardous drinkersAbstinent daysCessation failureAlcohol usersDose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTXA brief 7-day estimate of alcohol consumption for use in smoking cessation clinical trials
Toll BA, Leeman RF, McKee SA, O'Malley SS. A brief 7-day estimate of alcohol consumption for use in smoking cessation clinical trials. Addictive Behaviors 2008, 33: 1606-1609. PMID: 18722721, PMCID: PMC2577001, DOI: 10.1016/j.addbeh.2008.07.007.Peer-Reviewed Original ResearchConceptsCessation clinical trialHeavy drinking daysNumber of drinksClinical trialsDays abstinentDrinking daysTimeline FollowbackSmoking cessation clinical trialAlcohol useTreatment periodSmoking relapseAlcohol consumptionCessation studyTotal abstinenceBaselineDrinking dataTime burdenAbstinentAbstinenceTrialsDaysTreatmentMost studiesLong periodLonger time windowMessage Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender
Toll BA, Salovey P, O'Malley SS, Mazure CM, Latimer A, McKee SA. Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender. Nicotine & Tobacco Research 2008, 10: 195-200. PMID: 18188760, PMCID: PMC2527723, DOI: 10.1080/14622200701767803.Peer-Reviewed Original ResearchConceptsMessage framing interventionsRisk of cessationSmoking cessationLung cancerClinical trialsGain-framed messagesHigh riskSmoking relapseHealth message framingHealth problemsLoss-framed messagesSmokingFraming interventionCessationNumber of daysInfluence of genderInterventionRiskRisk perceptionWomenMedian splitGain-framed conditionDaysMenGender differences
2007
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.
Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & Tobacco Research 2007, 9: 597-605. PMID: 17454716, PMCID: PMC2527736, DOI: 10.1080/14622200701239662.Peer-Reviewed Original ResearchConceptsMedication Adherence QuestionnaireCigarette smokersNicotine patchAdherence QuestionnaireMedication adherenceNicotine patch useSmoking cessation outcomesPill-taking behaviorSample of smokersDrug plasma levelsBrief screening toolNonadherence factorsMedication useUnintentional nonadherencePlasma levelsCessation outcomesClinical trialsTreatment outcomesDrug levelsPredictive validitySmokersMAQ scoresNonadherenceScreening toolFactor 1Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study
Toll BA, Schepis TS, O’Malley S, McKee SA, Krishnan-Sarin S. Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study. Drug And Alcohol Dependence 2007, 89: 302-305. PMID: 17320313, PMCID: PMC2475673, DOI: 10.1016/j.drugalcdep.2007.01.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive Agents, Second-GenerationBehavior TherapyBupropionCircadian RhythmDelayed-Action PreparationsFemaleHumansMaleMiddle AgedMotivationNicotineOutcome Assessment, Health CarePrognosisSecondary PreventionSmokingSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTobacco Use DisorderConceptsFirst cigaretteSmoking relapseEnd of treatmentCessation treatment outcomeInitial cigaretteWithdrawal symptomsClinical trialsQuit dayTreatment outcomesNovel predictorRelapseCigarettesPreliminary studyTime pointsGreater decreaseCravingSubjective responsesSubjective reactivityDaysFuture studiesSignificant changesWithdrawalPredictorsResponseBupropion
2005
Do Daily Interactive Voice Response Reports of Smoking Behavior Correspond With Retrospective Reports?
Toll BA, Cooney NL, McKee SA, O'Malley SS. Do Daily Interactive Voice Response Reports of Smoking Behavior Correspond With Retrospective Reports? Psychology Of Addictive Behaviors 2005, 19: 291-295. PMID: 16187808, PMCID: PMC2527779, DOI: 10.1037/0893-164x.19.3.291.Peer-Reviewed Original ResearchConceptsCigarette consumptionSmoking cessation clinical trialTimeline follow-back methodCessation clinical trialSmoking cessation trialCessation trialClinical trialsInteractive voice response systemSmoking behaviorCigarette useVoice response systemTLFBRetrospective reportsTrialsReportIVR systemEntire sampleParticipantsDaily reportsSmokingCompliance